Alector surges on licensing agreement with Genentech
The share price surged following the news of the licensing agreement signed between Alector and Genentech.
Considering its position between the support ($1.79) and resistance ($2.61) levels, an entry can be considered based on a rebound from oversold conditions and news of a licensing agreement; however, given the downward deviation from the MA-Align and the low volume ratio, one should approach with caution while closely monitoring whether it breaks through the resistance level.
Take profit near the resistance level of $2.61 reached at the 20th high, and cut losses if the support level of $1.79 is breached — currently rebounding from the RSI 25.6 oversold territory due to news impact, but with the MA-Align in a downward breakdown state and a low volume ratio, respond by cautiously monitoring whether it breaks through the resistance level.
At the time of entry, the RSI (14) stands at 25.6, indicating an oversold condition, and the moving averages are in a non-aligned state. Trading volume is at 0.80x the 20-day average, and the 7-day volatility (rate of change) recorded -10.4%.
Although a rebound was anticipated based on the partnership agreement news and the oversold condition with an RSI of 25.6, the trade ultimately resulted in a failure with a loss of -12.7%. It was confirmed that the primary reasons for the failure to break through the resistance line and the subsequent reversal into a downtrend were that the MA-Align was in a downward departure state at the time of entry and trading volume was insufficient at 0.80 times the 20-day average.
I will strictly reflect in my next trades that, under conditions of a non-aligned moving average arrangement and low trading volume, a trending rebound is difficult even in the presence of favorable news. Going forward, even in oversold zones, I will exercise greater caution and enter only after confirming that trading volume is supported and the moving averages have recovered to a bullish alignment.